Redeye states its view on Hoylu’s Q4 2022 report, announced earlier today.
Redeye comments on Tessin’s Q4 results, which came in lower than expected in terms of sales and prof...
Redeye saw a sales development that was not far off our expectations.
Redeye leaves its comments on Stille’s Q4 2022 report.
Redeye provides an initial take on Optomed’s Q4 2022 report.
Redeye states AVTECH's Q4'22 report was in line with Redeye's estiamtes and in line with preliminary...
Addlife stänger böckerna för 2022 och redovisar åter organisk tillväxt.
Redeye concludes that Q4 came in somewhat below its estimates, but that sensor sales has now picked ...
CirChem har nyligen presenterat sin Q4-rapport vilken var i nära linje med våra förväntningar och un...
Redeye comments on EG7’s Q4-results which was stronger than expected with EBITDA coming in 14% above...
Redeye comments on Westpay’s Q4 results, which showed slower growth than in recent quarters, while m...
After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, st...
Redeye raises its Base Case and forecasts slightly following a solid report with better-than-expecte...
Redeye updates on Stillfront following the company's Q4-report which saw stronger EBITDA than expect...
Redeye makes minor adjustments to its estimates but maintains its fair value range and base case.
Redeye returns with a review following BIMobject’s Q4 report which held no major surprises.
Q4 report due Wednesday, 22 February, 07:00 CET '23e-'24e EBIT down 4-3%, mainly due to FX 12-5x EBI...
Taaleri's Q4 was a mixed bag with higher-than-anticipated carry, while investment operations fell sh...
Like most other Nordic real estate companies, Cibus will likely focus mainly on its balance sheet an...
Redeye comments on Ultimovacs’ Q4 2022 report, and we judge that INITIUM and NIPU top-line data in H...
